Core Viewpoint - 康诺生物制药股份有限公司 is preparing for an IPO on the Hong Kong Stock Exchange, with significant revenue fluctuations and a focus on mitochondrial medicine and health products [1][2][5]. Group 1: Company Overview - 康诺生物, established in 2017, specializes in the research and commercialization of drugs related to mitochondrial dysfunction, targeting cardiovascular diseases, neurodegenerative diseases, reproductive health, and aging [5]. - The market for mitochondrial medicine products in China is projected to grow from 95 billion yuan in 2020 to 179 billion yuan by 2024, with a compound annual growth rate (CAGR) of 17.1%, and expected to reach 308.1 billion yuan by 2035, with a CAGR of 29.5% from 2024 to 2035 [5]. Group 2: Financial Performance - 康诺生物's revenue for 2023 and 2024 was 3.03 billion yuan and 2.4 billion yuan, respectively, representing a decline of approximately 20.8%, while net profit dropped by 57.4% to 795.2 million yuan and 339.05 million yuan [6]. - In the first three quarters of 2025, the company reported a revenue of 238 million yuan, a year-on-year increase of 33%, and a net profit of 53.41 million yuan, up 93% [7]. Group 3: Product Portfolio - The flagship product, 恩艾地 (NAD⁺ injection), accounted for 65.2% of total revenue in the first three quarters of 2025, with revenues of 134 million yuan, 106 million yuan, and 155 million yuan in 2023, 2024, and 2025 respectively [9]. - The company has a total of 20 commercialized drugs, with 15 included in the national medical insurance directory, but 恩艾地 is not among them, which could impact future revenues if it is included [10]. Group 4: Future Prospects and R&D - 康诺生物 plans to use IPO proceeds to fund the development of several candidate drugs, including those targeting acute myocardial infarction and chronic heart failure, with clinical trials expected to complete by Q1 2027 [11]. - The company also aims to invest in the construction of smart biological factories and upgrade its sales and distribution networks, as well as digital infrastructure [11].

Group 1 - The core business of the company is focused on addressing diseases caused by mitochondrial dysfunction, utilizing NAD+ in areas such as cardiovascular diseases, neurodegenerative diseases, reproductive health, and aging [1] - The flagship commercial drug of the company is Enadi (injectable coenzyme I), alongside other products including Qianrongmei, Tianshu, injectable nitroprusside, and 16 generic drugs covering four major therapeutic areas [1] - As of January 16, 2026, the company has 20 drugs in the production stage [1] Group 2 - The market size for mitochondrial medicine products in China is expected to grow rapidly, projected to increase from 17.9 billion RMB in 2024 to 308.1 billion RMB by 2035, with a compound annual growth rate of 29.5% [1]